ReviewInflammopharmacology2026
Pharmaco-therapeutic modulation of the Glo1-Nrf2-RAGE functional network in chronic inflammation: polyphenols in the context of current anti-inflammatory therapy.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drugging trained immunity: immunometabolic and epigenetic control of maladaptive inflammatory memory in chronic inflammatory diseases.Immunologic research · 2026Review
- Polyphenol-based modulation of the Glo1-Nrf2-RAGE axis in diabetes and neurodegeneration: mechanistic evidence, translational constraints, and critical appraisal.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation is a central driver of numerous disorders, including metabolic, cardiovascular, neurodegenerative, autoimmune, and malignant diseases. Although current anti-inflammatory pharmaco-therapeutic strategies, including nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, disease-modifying antirheumatic drugs, and biologic agents, can reduce inflammatory burden and improve clinical outcomes, their long-term use is often limited by adverse effects, incomplete disease control, treatment resistance, and poor correction of upstream oxidative and glycation-related mechanisms. In this context, the interconnected Glo1-Nrf2-RAGE network has emerged as a pharmacologically relevant framework that links carbonyl stress, oxidative injury, and inflammatory signal amplification in chronic diseases. This review examines the therapeutic significance of this axis and evaluates polyphenolic compounds as emerging modulators of Glo1-, Nrf2-, and RAGE-associated pathways. Polyphenols such as curcumin, epigallocatechin gallate, resveratrol, and related phenolics exhibit anti-inflammatory effects in preclinical models by enhancing antioxidant defense, attenuating AGE-RAGE signaling, and reducing pro-inflammatory mediators. However, their clinical translation remains constrained by poor bioavailability, variable pharmacokinetics, lack of dose standardization, and limited human evidence. Positioning polyphenols within the broader landscape of anti-inflammatory therapy helps clarify their current value as adjunctive modulators or lead structures for future therapeutic development targeting chronic inflammation.
Indexed as
Identifiers
42053959What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.